Related by context. All words. (Click for frequent words.) 78 neoadjuvant chemotherapy 78 adjuvant radiotherapy 76 chemoradiotherapy 75 preoperative chemotherapy 75 chemoradiation therapy 74 adjuvant radiation 73 sentinel lymph node biopsy 73 neoadjuvant 73 lymphadenectomy 72 cytoreduction 72 postoperative chemotherapy 72 resectable 72 cytoreductive surgery 72 TACE 72 locoregional recurrence 72 biochemical recurrence 72 locoregional 72 adjuvant therapy 72 concurrent chemoradiation 71 cystectomy 71 SLNB 71 metastatic RCC 71 curative resection 71 external beam radiotherapy 71 neoadjuvant treatment 71 lymph node dissection 71 chemoradiation 71 distant metastases 71 radical cystectomy 71 hepatic metastases 71 chemoembolization 70 radical nephrectomy 70 recurrent glioblastoma multiforme 70 debulking surgery 70 clinically localized prostate 70 biochemical relapse 70 androgen deprivation 70 5-fluorouracil/leucovorin 70 distant metastasis 70 FOLFOX4 70 adjuvant chemotherapy 69 peritoneal carcinomatosis 69 liver metastases 69 nodal metastasis 69 adjuvant therapies 69 IV NSCLC 69 nephrectomy 69 axillary dissection 69 cytoreductive nephrectomy 69 EUS FNA 69 Doxil ® 69 micrometastases 69 metastatic renal cell carcinoma 69 Radical prostatectomy 69 colorectal liver metastases 69 pT2 69 pancreatic adenocarcinoma 68 mucinous 68 nonmetastatic 68 medically inoperable 68 ALND 68 recurrent GBM 68 Adjuvant chemotherapy 68 tumor recurrence 68 allogeneic stem cell 68 preoperative radiotherapy 68 tumor resection 68 nephron sparing surgery 68 gemcitabine chemotherapy 68 pelvic lymphadenectomy 68 postoperative radiotherapy 68 non squamous NSCLC 68 pCR 68 lymph node involvement 68 metastatic GIST 68 retroperitoneal 68 liver resection 68 radiochemotherapy 68 metastatic colorectal 68 recurrent NSCLC 68 oncologic outcomes 68 cisplatin chemotherapy 68 Neoadjuvant 68 stage IIIB 68 orchiectomy 68 partial nephrectomy 68 unresectable 68 prostate carcinoma 68 EBRT 68 breast carcinoma 68 VATS lobectomy 67 R0 resection 67 XELOX 67 chemotherapeutic regimens 67 sentinel node biopsy 67 radioiodine therapy 67 precursor lesions 67 renal tumors 67 urothelial carcinoma 67 recurrent metastatic 67 FDG-PET/CT 67 invasive carcinoma 67 unresectable tumors 67 metastatic lesions 67 lymph node metastases 67 parathyroidectomy 67 KRAS mutation 67 transurethral resection 67 intravenous bisphosphonates 67 axillary lymph nodes 67 anthracycline taxane 67 Accelerated Partial Breast Irradiation 67 allogeneic SCT 67 radiotherapy RT 67 GnRH agonists 67 esophagectomy 67 stage IIIb IV 67 neoadjuvant chemoradiotherapy 67 advanced adenomas 67 seminoma 67 heavily pretreated patients 67 malignant pleural mesothelioma 67 epirubicin 67 HER2 positive metastatic breast 67 taxane therapy 67 liver metastasis 67 abdominal hysterectomy 67 localized renal 67 Hepatocellular Carcinoma HCC 67 OPAXIO 67 chemo radiotherapy 66 TTF Therapy 66 fluorouracil 66 metastatic gastric 66 cervical carcinoma 66 renal cell carcinomas 66 estramustine 66 Lymph node 66 vandetanib 66 antiangiogenic therapy 66 Gliadel Wafer 66 relapsed ovarian cancer 66 hepatic resection 66 sleeve lobectomy 66 wedge resection 66 endometrial carcinoma 66 intestinal metaplasia 66 mRCC 66 Mitomycin C 66 surgical debulking 66 fine needle aspiration 66 Surgical resection 66 5FU 66 HoLEP 66 underwent resection 66 PSADT 66 axillary lymph node 66 CMV disease 66 prostate cancer CaP 66 fibrinolytic therapy 66 carboplatin paclitaxel 66 NMIBC 66 RECIST Response Evaluation Criteria 66 papillary renal cell carcinoma 66 salpingo oophorectomy 66 lobular carcinoma 66 differentiated thyroid 66 methotrexate therapy 66 cytotoxic therapy 66 TURBT 66 relapsed SCLC 66 mediastinoscopy 66 BEACOPP 66 underwent surgical resection 65 bone metastasis 65 recurrent ovarian 65 Fludara 65 postoperative morbidity 65 intravesical infusion therapy 65 fallopian tube carcinoma 65 Taxotere ® 65 prostate TURP 65 axillary lymph node dissection 65 mycophenolate mofetil 65 HER2 overexpression 65 myeloablative 65 tumor excision 65 radical prostatectomy RP 65 advanced adenoma 65 zoledronic acid 65 radiofrequency ablation RFA 65 ICD implantation 65 histologic 65 chemoresistant 65 trabectedin 65 perioperative morbidity 65 lymph node removal 65 pT3 65 mitomycin C 65 thoracoscopic lobectomy 65 pneumonectomy 65 metastases 65 Allovectin 7 ® 65 Adjuvant therapy 65 metastatic neuroendocrine tumors 65 liposomal doxorubicin 65 mCRC patients 65 gastrointestinal stromal tumors 65 endosonography 65 EGFR TKI 65 completely resected 65 Platinol ® cisplatin 65 axillary node dissection 65 trastuzumab 65 FDG PET 65 decitabine 65 reimplantation 65 stage IIIA 65 trastuzumab Herceptin ® 65 DMARD 65 docetaxel chemotherapy 65 platinum refractory 65 locoregional disease 65 invasive lobular carcinoma 65 node dissection 65 Kaplan Meier analysis 65 radical prostatectomy 65 KRAS status 65 LHRH receptor positive 65 sorafenib Nexavar 65 peritoneal cancer 65 situ LCIS 65 ductal carcinomas 65 adjuvant cisplatin 65 DOXIL 65 histological subtype 65 vinorelbine 65 relapsed MM 65 Zevalin consolidation 65 coronary stenting 65 Halaven 65 percutaneous cryoablation 65 Surgical excision 65 HIPEC 65 postoperative mortality 65 urothelial cancer 65 chemotherapy docetaxel 65 percutaneous biopsy 65 nodal dissection 65 metastatic disease 65 pegylated liposomal doxorubicin 64 resistant hormone refractory 64 gastrointestinal stromal tumors GIST 64 TAXOTERE R 64 basal cell carcinoma BCC 64 colorectal cancer liver metastases 64 perioperative complications 64 mitoxantrone 64 histopathologic examination 64 FOLPI 64 chemotherapy cisplatin 64 sarcomatoid 64 Free Survival PFS 64 lung metastasis 64 chlorambucil 64 histologically confirmed 64 allogeneic HSCT 64 HGPIN 64 antimicrobial prophylaxis 64 intraperitoneal chemotherapy 64 anthracycline containing 64 core needle biopsy 64 Trastuzumab 64 KRAS mutations occur 64 standard chemotherapy regimen 64 nab paclitaxel 64 Lenalidomide 64 adrenalectomy 64 complete cytogenetic response 64 stage IIIB IV 64 nodal metastases 64 taxane chemotherapy 64 perioperative mortality 64 operable breast cancer 64 TRUS biopsy 64 epithelial ovarian 64 STRIDE PD 64 HNSCC 64 GnRH agonist 64 resected 64 Sentinel node biopsy 64 oral clodronate 64 CIN3 64 radical retropubic prostatectomy 64 CHOP chemotherapy 64 RALP 64 nonsmall cell lung cancer 64 SCCHN 64 PROCHYMAL 64 clodronate 64 colon resection 64 invasive coronary angiography 64 Median progression 64 dacarbazine chemotherapy 64 Radiofrequency ablation 64 hepatectomy 64 octreotide LAR 64 Cystectomy 64 metastatic lung cancer 64 overlapping toxicities 64 pulmonary metastases 64 fulvestrant 64 metachronous 64 F FDG PET 64 metastatic malignant 64 HER2 positive cancers 64 bleomycin 64 biliary tract cancer 64 rFVIIa 64 pamidronate 64 fallopian tube cancers 64 adriamycin 64 cisplatin resistant 64 liver transplant recipients 64 Irinotecan 64 antitumor effect 64 HER2 negative 64 endometrial hyperplasia 64 squamous histology 64 SLN biopsy 64 bevacizumab Avastin 64 HSCT 64 prior nephrectomy 64 tumor histology 64 mutated KRAS 64 thymoma 64 pathologic diagnosis 64 node metastases 64 cisplatin gemcitabine 64 lobectomy 64 Ceplene/IL-2 64 FOLFIRI 64 leiomyomas 64 PSA nadir 64 PCa 64 androgen suppression 64 pathologic examination 64 gemcitabine carboplatin 64 allogeneic hematopoietic stem cell 64 lung resection 64 Proxinium TM 64 transarterial chemoembolization 64 BCG refractory 64 metastatic HRPC 64 conventional angiography 64 hip resurfacing arthroplasty 64 Vectibix monotherapy 64 Gemcitabine 64 chemotherapeutic regimen 64 placebo dexamethasone 64 infusional 5-FU/LV 64 everolimus eluting stents 64 GISTs 64 sentinel node 64 hypofractionated 64 curative therapy 64 Metastatic breast cancer 64 Torisel 64 reperfusion therapy 64 neoadjuvant radiation 64 ELOXATIN 64 multimodality therapy 64 Velcade bortezomib 64 standard chemotherapy regimens 63 CYPHER Stent 63 pemetrexed 63 axillary node 63 TURP 63 hepatocellular carcinoma HCC 63 5-FU/LV 63 lymph node metastasis 63 hematologic toxicity 63 endometrial adenocarcinoma 63 elective PCI 63 Paraplatin ® 63 anastrazole 63 metastatic malignant melanoma 63 ASCUS 63 adjuvant tamoxifen 63 Natalizumab 63 metastatic bladder 63 paclitaxel eluting stents 63 palliation 63 Hurthle cell 63 surgical excision 63 lenalidomide Revlimid R 63 #F FDG PET 63 oral Hycamtin 63 erlotinib Tarceva ® 63 micrometastasis 63 gefitinib Iressa 63 laparoscopic radical prostatectomy 63 castrate resistant 63 TEMODAL 63 Papillary 63 thyroid nodules 63 percutaneous drainage 63 Nexavar sorafenib 63 gastric adenocarcinoma 63 prognostic indicator 63 bladder carcinoma 63 thromboembolic events 63 EGFR expressing mCRC 63 pulmonary artery banding 63 catheter angiography 63 adenomatous polyps 63 paclitaxel Taxol R 63 CsA 63 Subgroup analyzes 63 HER2 positive 63 Metastatic 63 ACR# responses 63 MGd 63 #Gy 63 histologies 63 allogeneic bone marrow 63 intravesical therapy 63 recurrent prostate cancer 63 nonoperative treatment 63 dacarbazine 63 colectomy 63 intraductal 63 temsirolimus 63 revascularization procedures 63 Stereotactic Body Radiation Therapy 63 prostate cancer CRPC 63 flutamide 63 imatinib therapy 63 QuadraSphere 63 renal transplantation 63 progression TTP 63 hepatorenal syndrome 63 alkylating agent 63 autologous chondrocyte implantation 63 sustained virological response 63 TORISEL 63 cervical lymph node 63 transarterial 63 refractory colorectal cancer 63 daunorubicin 63 resections 63 preoperative staging 63 cancer mCRC 63 KRAS wild 63 irinotecan chemotherapy 63 ovarian carcinoma 63 needle aspiration 63 epithelial tumors 63 docetaxel Taxotere ® 63 T1c 63 atypical hyperplasia 63 intra arterial chemotherapy 63 gastrointestinal stromal tumor GIST 63 cytotoxic chemotherapy 63 APTIVUS r 63 ALA PDT 63 gastrectomy 63 metastatic carcinoma 63 thromboembolic disease 63 ductal cancer 63 androgen independent 63 operable pancreatic cancer 63 alteplase 63 situ DCIS 63 prospectively stratified 63 β blockers 63 CIMZIA ™ 63 ixabepilone 63 urine cytology 63 YONDELIS 63 non squamous 63 pancreatic islet cell 63 tamoxifen therapy 63 calcineurin inhibitors 63 Liver transplantation 63 FOLFOX6 63 CYT# potent vascular disrupting 63 strontium ranelate 63 resection 63 SIR Spheres 63 MAGE A3 ASCI 63 perioperatively 63 pretargeting 63 oblimersen 63 pertuzumab 63 surgical revascularization 63 EGFR mutation positive 63 posaconazole 63 K ras mutations 63 antithrombotic therapy 63 invasive bladder 63 HER2 expression 63 Hycamtin 63 sirolimus eluting stents 63 ADVEXIN therapy 63 metastatic HER2 negative 63 BCIRG 63 surgically resectable 63 epithelial ovarian cancer 63 HBeAg seroconversion 63 Pemetrexed 63 skeletal metastases 63 coronary revascularization 63 lobular carcinomas 63 baseline LDH 63 graft occlusion 63 FOLFOX 63 bevacizumab Avastin ® 63 SBRT 63 dacarbazine DTIC 63 doxorubicin 63 heavily pretreated 63 docetaxel 63 gefitinib 63 Flu Cy 63 contralateral breast 63 tumor shrinkage 63 excisional biopsy 63 sipuleucel T 63 ER CHOP 63 adjuvant trastuzumab 63 severe neutropenia 63 para aortic 63 detectable HCV RNA 63 ximelagatran 63 metastatic castration resistant 63 spiral computed tomography 63 tumor necrosis 62 definite stent thrombosis 62 EFAPROXYN 62 Faslodex 62 esophageal carcinoma 62 fluoropyrimidine 62 Bezielle 62 extrapleural pneumonectomy 62 postoperative complication 62 carotid endarterectomy CEA 62 T1a 62 transplantation HCT 62 gadolinium enhanced 62 topotecan 62 brain metastases 62 cetuximab 62 gastroesophageal junction 62 reinfarction 62 HER2 positive breast cancer 62 vaginal hysterectomy 62 bilateral orchiectomy 62 renal carcinoma 62 metastatic prostate cancer 62 KRAS mutant tumors 62 endometrial biopsy 62 ASCT 62 anti angiogenic therapy 62 lung metastases 62 prospectively defined 62 BEXXAR Therapeutic Regimen 62 cediranib 62 fibrinolysis 62 remission induction 62 paclitaxel carboplatin 62 transthoracic 62 BRCA2 mutation carriers 62 MYLOTARG 62 subgroup analyzes 62 laparoscopically assisted 62 CR nPR 62 stent implantation 62 CIMZIA TM 62 bone scintigraphy 62 malignant growths 62 GLIADEL R Wafer 62 pancreatic carcinoma 62 median PFS 62 RECIST criteria 62 Xanafide 62 Response Evaluation Criteria 62 pegylated interferon alfa 2b 62 evaluable 62 BRCA deficient 62 colorectal carcinoma 62 imatinib Gleevec 62 bevacizumab 62 resected pancreatic cancer 62 axillary nodes 62 galiximab 62 thyroglobulin 62 situ CIS 62 squamous cell carcinoma SCC 62 cranial radiation 62 histologic subtype 62 paclitaxel Taxol ® 62 optical colonoscopy 62 BRIM2 62 advanced neoplasia 62 remission CR 62 hormone refractory 62 cisplatin 62 endoscopic ultrasound 62 SUVmax 62 coinfected patients 62 adenoma recurrence 62 doxorubicin cyclophosphamide 62 Endometrial 62 EBUS FNA 62 Kaplan Meier 62 eribulin mesylate 62 noninvasive outpatient 62 doublet chemotherapy 62 microsphere therapy 62 thrombolytic therapy 62 pancreatic resection 62 aromatase inhibitor therapy 62 gemcitabine cisplatin 62 intensity modulated radiotherapy IMRT 62 hormone receptor status 62 advanced hepatocellular carcinoma 62 riociguat 62 percutaneous intervention 62 Subgroup analysis 62 hypervascular tumors 62 Erlotinib 62 variceal hemorrhage 62 Follicular Lymphoma 62 castration resistant prostate cancer 62 immunosuppressive regimens 62 nonoperative 62 carcinoid 62 azacitidine 62 hepatic arterial 62 transesophageal echocardiography 62 intravesical 62 breast conserving 62 idarubicin 62 neoplastic cells 62 FUSILEV enhances 62 interferon alfa 62 resected tumors 62 trans urethral resection 62 FOLFIRI alone 62 colorectal adenocarcinoma 62 endarterectomy 62 Tavocept 62 CTEPH 62 mycophenolic acid 62 skin sparing mastectomy 62 orchidectomy 62 postsurgical 62 refractory ovarian cancer 62 androgen ablation 62 sonographically guided 62 sunitinib 62 sorafenib tablets 62 MACCE 62 antiangiogenic agent 62 orthotopic 62 bronchogenic carcinoma 62 nonmelanoma skin cancers 62 Intraoperative Radiation Therapy IORT 62 LHRH agonists 62 FluCAM 62 immunosuppressive regimen 62 hormone deprivation 62 tamsulosin 62 endoscopic resection 62 carotid artery stenting CAS 62 gemcitabine 62 APTIVUS ritonavir 62 PSMA ADC 62 adenomatous 62 occult metastases 62 cabazitaxel 62 virologic responses 62 goserelin 62 intraperitoneal therapy 62 OPCAB 62 Xelox 62 azacytidine 62 HER2 positive breast 62 gemcitabine Gemzar 62 ductal 62 Percutaneous Coronary Intervention 62 follicular NHL 62 endocrine therapies 62 paclitaxel cisplatin 62 beam radiotherapy 62 total thyroidectomy 62 thalidomide Thalomid 62 metastatic liver 62 Fluorouracil 62 autologous SCT 62 palifermin 62 balloon brachytherapy 62 pelvic lymph node dissection 62 leiomyoma 62 coronary arteriography 62 efalizumab 62 FOLFIRINOX 62 malignant polyps 62 CIN2 + 62 RECIST 61 autologous hematopoietic stem cell 61 iniparib BSI 61 AA Amyloidosis 61 HBeAg positive patients 61 squamous 61 ELACYT 61 Squamous Cell Carcinoma 61 antithymocyte globulin 61 transrectal ultrasound guided 61 ABVD 61 bone metastases 61 FASLODEX 61 GVAX Pancreas Vaccine 61 minimally symptomatic 61 Kaplan Meier method 61 androgen suppression therapy 61 Ductal carcinoma 61 malignant neoplasms 61 comparator arm 61 endoscopic ultrasonography 61 Carcinoma 61 palliative radiotherapy 61 conformal radiotherapy 61 depsipeptide 61 bladder tumors 61 pain palliation 61 Circulating tumor cells 61 Folfox 61 specific antigen PSA 61 conventional coronary angiography 61 clinico pathological 61 hormone receptor negative 61 colorectal adenoma 61 TRUS 61 NSCLC 61 pancreatic lung 61 allogeneic transplant 61 invasive aspergillosis 61 immunohistochemical analysis 61 Gefitinib 61 anaplastic 61 metastatic lymph nodes 61 retransplantation 61 free survival PFS 61 upper endoscopy 61 surrogate endpoint 61 EGFR mutation 61 ovarian suppression 61 cranial irradiation 61 papillary carcinoma 61 HBeAg negative 61 reoperation 61 hepatocellular carcinomas 61 endoscopic retrograde 61 Tumor Response 61 achieved CCyR 61 enucleation 61 GIST tumors 61 Gleevec resistant 61 intratumoral 61 cinacalcet 61 carotid artery stenting 61 cervical lymph nodes 61 TNF antagonist 61 prednisone prednisolone 61 hENT1 61 ErbB2 positive 61 decompressive surgery 61 cyclophosphamide methotrexate 61 clopidogrel pretreatment 61 advanced unresectable 61 paricalcitol 61 anastrozole 61 CCyR 61 PNH patients 61 fondaparinux 61 #F FDG 61 candidemia 61 glomerular filtration 61 Sentinel Lymph Node Biopsy 61 Gemzar ® 61 Hycamtin ® 61 adecatumumab 61 lymphatic mapping 61 surgical resection cavity 61 docetaxel Taxotere 61 follicular lymphomas 61 mycosis fungoides 61 neoplastic 61 invasive candidiasis 61 HRPC 61 sorafenib 61 anticancer therapy 61 taxane refractory 61 RTOG 61 HER2 positive tumors 61 Cetuximab 61 hormone receptor positive 61 Solid Tumors RECIST 61 ERCP 61 ultrasonographic 61 pancreatic prostate 61 HBV infections 61 Renal Cell Carcinoma 61 partial remissions 61 plain radiographs 61 vismodegib 61 IFN alfa 61 Elitek 61 elacytarabine 61 pancreatectomy 61 angiographic restenosis 61 immunosuppressive agents 61 resectable pancreatic cancer 61 radiolabeled TM# 61 prostatectomy 61 NovoTTF 61 endocrine therapy 61 endometrioid 61 Temsirolimus 61 revascularization procedure 61 VELCADE melphalan 61 esophageal resection 61 IORT 61 LEUKINE 61 PREZISTA r 61 EGFR expressing 61 postintervention 61 intracavitary 61 total abdominal hysterectomy 61 doxorubicin docetaxel 61 glycoprotein IIb IIIa inhibitors 61 imatinib 61 nephron sparing 61 Intravenous CP 61 biologic DMARD 61 metastatic CRC 61 metastatic lesion 61 tumor lysis syndrome 61 lenalidomide dexamethasone 61 Resection 61 portal vein thrombosis 61 transvaginal sonography 61 cytogenetic response 61 prostate adenocarcinoma 61 Coronary artery bypass 61 tumors GIST 61 MitraClip device 61 autograft 61 FDG PET imaging 61 oophorectomy 61 immunohistochemical 61 paragangliomas 61 pheochromocytoma 61 TAXOTERE ® 61 metastatic prostate 61 etoposide 61 hepatic metastasis 61 radiation therapy 61 oral ridaforolimus 61 PROSTVAC TM 61 mediastinal lymph nodes 61 ERBITUX Cetuximab 61 hyperthermia therapy 61 sentinel nodes 61 sunitinib malate 61 anthracyclines 61 VIDAZA 61 transplantation HSCT 61 iodixanol 61 cyclophosphamide 61 sentinel lymph node 61 premalignant 61 carcinoma HCC 61 ZOLINZA 61 colorectal metastases 61 ductal breast cancer 61 Venous thromboembolism 61 malignant ascites 61 metastatic tumors 61 trabeculectomy 61 thymectomy 61 pelvic lymph nodes 61 crizotinib PF # 61 hepatocellular carcinoma 61 surgical biopsy 61 adjuvant hormonal therapy 61 invasive carcinomas 61 postoperative pulmonary 61 invasive ductal 61 repigmentation 61 antibiotic prophylaxis 61 transabdominal 61 carcinoid tumors 61 cytotoxic therapies 61 soft tissue sarcomas 61 fibrinolytic 61 hormonal therapies 61 Androgen Deprivation Therapy 61 trastuzumab Herceptin 61 metastatic pancreatic 61 scintigraphic 61 choriocarcinoma 61 Metastatic colorectal cancer 61 radiotherapy SBRT 61 evaluable patients 61 thymic carcinoma 61 NATRECOR ® 61 virologic response 61 Herceptin trastuzumab 61 binary restenosis 61 ZACTIMA 61 ibandronate 61 multivariate Cox 61 chemotherapy regimens 61 histologically 61 axitinib 61 ProstaScint 61 5 fluorouracil 61 hematopoietic cancers 61 Median survival 61 AVODART 61 nephrotoxicity 61 prognostic variables 61 precancerous cervical lesions 61 OncoVEX GM CSF 61 colonography 61 median sternotomy 61 capecitabine Xeloda 61 plus dexamethasone 61 lymphocytosis 61 complete remissions 61 metastatic castrate resistant 61 adenoma 61 aromatase inhibitors AIs 61 pazopanib 61 laparoscopic radical nephrectomy 61 empiric therapy 61 cerebral angiography 61 morphometric vertebral fractures 60 angiographic outcomes 60 histopathologic 60 SUTENT 60 radiation therapy SBRT 60 interferon beta therapy 60 metastatic renal cell 60 Gastrointestinal Stromal Tumors 60 MGUS 60 antiandrogen 60 xenograft models 60 hepatocellular cancer 60 sunitinib Sutent 60 Pertuzumab 60 atypical ductal hyperplasia 60 Bevacizumab Avastin 60 interferon ribavirin 60 premalignant lesions 60 mammographic density 60 superficial bladder cancer 60 coronary angiography 60 clinicopathological features 60 haematologic 60 benign nodules 60 genotypic resistance 60 laparoscopic nephrectomy 60 tamoxifen Nolvadex ® 60 CBLC# 60 Capsule endoscopy 60 ablative therapy 60 pelvic malignancies 60 leucovorin 60 mg kg dose 60 histopathological 60 TNF blocker therapy 60 metastatic cancer 60 extracranial 60 Bevacizumab 60 EBUS 60 Renal Cell Carcinoma RCC 60 PASI scores 60 urothelial bladder cancer 60 penetrating keratoplasty 60 extracapsular extension 60 ovarian malignancy 60 lymphovascular invasion 60 sustained virologic response 60 chronic GVHD 60 MammoSite RTS